Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 6, 2015, Pages 1110-1116

  Chen, Huan ^a   Liu, Kai Yan ^a   Xu, Lan Ping ^a   Chen, Yu Hong ^a   Han, Wei ^a   Zhang, Xiao hui ^a   Wang, Yu ^a   Qin, Ya Zhen ^a   Liu, Yan Rong ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute lymphoblastic leukemia; Haploidentical; Hematopoietic stem cell transplantation; Imatinib resistance; Philadelphia chromosome

Indexed keywords

ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; IMATINIB; METHOTREXATE; PREDNISONE; SEMUSTINE; THYMOCYTE ANTIBODY; VINCRISTINE; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; REAL TIME POLYMERASE CHAIN REACTION; T CELL DEPLETION; ACUTE DISEASE; ALLOTRANSPLANTATION; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; GRAFT VS HOST DISEASE; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; SIBLING; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

ACUTE DISEASE; ADULT; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMATINIB MESYLATE; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84947491779     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.02.009     Document Type: Article

References (35)

1. Lee K.H., Lee J.H., Choi S.J., et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005, 19:1509-1516.
2. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396-4407.
3. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460-466.
4. Mizuta S., Matsuo K., Yagasaki F., et al. Pre-transplant imatinib based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011, 25:41-47.
5. Schultz K.R., Carroll A., Heerema N.A., et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 2014, 28:1467-1471.
6. Forman S.J., O'Donnell M.R., Nademanee A.P., et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1987, 70:587-588.
7. Chao N.J., Blume K.G., Forman S.J., et al. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995, 85:3353-3354.
8. Lee H.J., Thompson J.E., Wang E.S., et al. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011, 117:1583-1594.
9. Fielding A.K., Rowe J.M., Richards S.M., et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009, 113:4489-4496.
10. Wassmann B., Pfeifer H., Goekbuget N., et al. Alternating versus concurrent schedules of imatinib and chemotherapy as frontline therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph1 ALL). Blood 2006, 108:1469-1477.
11. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408-1413.
12. Ribera J.M., Oriol A., Gonzalez M., et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: final results of the CSTIBES02 trial. Haematologica 2010, 95:87-95.
13. Bassan R., Rossi G., Pogliani E.M., et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010, 28:3644-3652.
14. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.
15. Xu L.P., Liu K.Y., Liu D.H., et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 2012, 47:1507-1512.
16. Wang Y., Liu D.H., Xu L.P., et al. Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012, 18:716-721.
17. Chen H., Liu K.Y., Xu L.P., et al. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Chin Med J (Engl) 2011, 124:246-252.
18. Chen H., Liu K.Y., Xu L.P., et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol 2012, 5:29.
19. Harris N.L., Jaffe E.S., Diebold J., et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000, 36(1):69-86.
20. Qin Y.Z., Liu Y.R., Zhu H.H., et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008, 30:317-323.
21. Beillard E., Pallisgaard N., van der Velden V.H., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 2003, 17:2474-2486.
22. Qin Y., Chen S., Jiang B., et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol 2011, 90:47-52.
23. National Comprehensive Cancer Network Clinical Practice Guideline in Oncology Chronic Myelogenous Leukemia. Version 2005, 2. Management of Imatinib Toxicity.
24. Laport G.G., Alvarnas J.C., Palmer J.M., et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 2008, 112:903-909.
25. Stirewalt D.L., Guthrie K.A., Beppu L., et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant 2003, 9:206-212.
26. Kebriaei P., Saliba R., Rondon G., et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant 2012, 18:584-592.
27. Doki N., Ohashi K., Oshikawa G., et al. Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution. Pathol Oncol Res 2014, 20:61-66.
28. Yanada M., Naoe T., Iida H., et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005, 36:867-872.
29. Mo X.D., Xu L.P., Zhang X.H., et al. Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups. Int J Cancer 2014, 136:1697-1707.
30. Wang Y., Liu D.H., Xu L.P., et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 2011, 17:821-830.
31. Baron F., Labopin M., Neiderwieser D., et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012, 26:2462-2468.
32. Valcárcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008, 26:577-584.
33. Li M., Zhang W., Wang J., et al. Impact of graft versus host disease on outcome of allogeneic peripheral blood stem cell transplantation for leukemia. Zhonghua Xue Ye Xue Za Zhi 2014, 35:428-433.
34. Khoury H.J., Guilhot F., Hughes T.P., et al. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 2009, 115:1381-1394.
35. Ottmann O., Dombret H., Martinelli G., et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110:2309-2315.